Open AccessUnmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study
Author(s) -
Edmonds Emily C.,
Ard M. Colin,
Edland Steven D.,
Galasko Douglas R.,
Salmon David P.,
Bondi Mark W.
Publication year - 2017
Publication title -
alzheimer's and dementia: translational research and clinical interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.49
H-Index - 30
ISSN - 2352-8737
DOI - 10.1016/j.trci.2017.11.001
Subject(s) - donepezil , neuropsychology , placebo , psychology , clinical trial , cognition , medicine , clinical psychology , dementia , disease , psychiatry , pathology , alternative medicine
Criteria for mild cognitive impairment (MCI) used in many clinical trials are susceptible to “false‐positive (FP)” errors that can be avoided by an actuarial psychometric approach. Methods Cluster analysis was applied to baseline neuropsychological test data from 756 MCI participants in the Alzheimer's Disease Cooperative Study donepezil trial. Treatment groups were compared after FP MCI cases were removed. Results Cluster analyses revealed three groups: “single‐domain amnestic MCI” (31%), “multi‐domain amnestic MCI” (39%), and “FP MCI” (30%). After removing FP MCI cases, the donepezil treatment group had a lower rate of progression to Alzheimer's disease and better performance on cognitive tests than the placebo/vitamin E group. Discussion Removal of FP MCI diagnoses unmasked beneficial effects of donepezil, despite a 30% reduction in sample size. MCI subject selection based on actuarial methods with comprehensive neuropsychological test data can result in more efficient clinical trials and improved ability to detect treatment effects.